`
`
`
`
`
`IN THE UNITED STATES DISTRICT COURT
`SOUTHERN DISTRICT OF NEW YORK
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case No. 22-CV-______
`
`
`
`
`
`
`
`ACUITAS THERAPEUTICS INC.,
` Plaintiff,
`
`v.
`GENEVANT SCIENCES GMBH AND
`ARBUTUS BIOPHARMA CORP.
`
`
`Defendants.
`
`
`
`
`RULE 7.1 DISCLOSURE STATEMENT
`
`Pursuant to Federal Rule of Civil Procedure 7.1, plaintiff Acuitas Therapeutics Inc.
`
`hereby states that it is a privately held corporation that has no parent corporation and that no
`
`publicly held corporation owns 10% or more of its stock.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 1:22-cv-02229-MKV Document 6 Filed 03/18/22 Page 2 of 2
`
`Dated: New York, New York
`
`March 18, 2022
`
`
`PAUL, WEISS, RIFKIND, WHARTON
`& GARRISON LLP
`
`By: /s/ Nicholas Groombridge_________
`
`Nicholas Groombridge
`Eric Alan Stone
`Josephine Young
`Allison C. Penfield
`1285 Avenue of the Americas
`New York, New York 10019-6064
`ngroombridge@paulweiss.com
`estone@paulweiss.com
`jyoung@paulweiss.com
`apenfield@paulweiss.com
`(212) 373-3000
`
`Saurabh Gupta*
`2001 K Street, NW
`Washington, DC 20006-1047
`sgupta@paulweiss.com
`(202) 223-7300
`
`Attorneys for Plaintiff Acuitas Therapeutics Inc.
`
`
` Pro hac vice application forthcoming
`
` *
`
`
`
`2
`
`